← Leaderboards
Ramiro Garzon
Ohio State University
$6,835,986
Attributed
$11,601,778
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,601,778 · 10
By mechanism
R01$10,302,841 · 5
R21$647,721 · 2
T32$546,912 · 2
P30$104,304 · 1
Top collaborators
- Guido Marcucci10 shared
- Carlo M Croce5 shared
- Adrienne M. Dorrance4 shared
- Parvathi Ranganathan4 shared
- Yvonne A. Efebera2 shared
- Claire F Verschraegen2 shared
- Steven K Clinton1 shared
Most similar at Ohio State University
Same institution · by research overlap
- Jack C. Yalowich$4,212,052
- Patrick Lee Green$10,720,230
- Michael A Caligiuri$65,062,344
- Mark J. Mitton-Fry$2,212,675
- Terry S Elton$3,572,815
Others in their field
Top investigators on “Proteins”
- David Heimbrook · Leidos Biomedical Research, Inc.$354,061,551
- Randall J Bateman · Washington University$187,292,085
- Paul S. Aisen · Cognition Therapeutics, Inc.$175,382,342
- Reisa A. Sperling · Banner Health$145,046,481
- Barton F Haynes · Duke University$136,029,850
- Joseph L Goldstein · University Of Texas Sw Med Ctr/Dallas$102,433,280
Research focus
ProteinsScheduleDoseNovel TherapeuticsReportingIn VivoCellsEpigenetic ProcessPreclinical StudyLeukemiaPharmacodynamicsBiologyMyelogenousPlayHematopoieticDrug KineticsComplexGenesIn VitroOverexpressionAcute Myelocytic LeukemiaOutcome ForecastGeneticBase
Grant awards (33)
Developing novel therapies to improve blood stem cell transplantation outcomes$630,428
R01 · FY2025 · HL · contact PI
Biology and Targeting of noncoding RNAs in AML$352,275
R01 · FY2025 · CA · contact PI
Developing novel therapies to improve blood stem cell transplantation outcomes$620,713
R01 · FY2024 · HL · contact PI
Developing novel therapies to improve blood stem cell transplantation outcomes$671,563
R01 · FY2023 · HL · contact PI
Biology and Targeting of noncoding RNAs in AML$342,534
R01 · FY2023 · CA · contact PI
Project 03: Leukemia Research (LR)$52,152
P30 · FY2023 · CA · contact PI
Developing novel therapies to improve blood stem cell transplantation outcomes$783,992
R01 · FY2022 · HL · contact PI
Biology and Targeting of noncoding RNAs in AML$349,713
R01 · FY2022 · CA · contact PI
Project 03: Leukemia Research (LR)$52,152
P30 · FY2022 · CA · contact PI
Biology and Targeting of noncoding RNAs in AML$356,850
R01 · FY2021 · CA · contact PI
Training Hematology and Oncology Fellows in Clinical Research$173,190
T32 · FY2021 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$528,129
R01 · FY2020 · CA
Biology and Targeting of noncoding RNAs in AML$356,850
R01 · FY2020 · CA · contact PI
Training Hematology and Oncology Fellows in Clinical Research$170,244
T32 · FY2020 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$515,834
R01 · FY2019 · CA
Biologic and Therapeutic Significance of miR-155 in AML$549,553
R01 · FY2018 · CA
Developing CRM1 inhibitors in AML$319,550
R01 · FY2018 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$554,107
R01 · FY2017 · CA
Developing CRM1 inhibitors in AML$319,550
R01 · FY2017 · CA · contact PI
Biologic and Therapeutic Significance of miR-155 in AML$574,050
R01 · FY2016 · CA
Developing CRM1 inhibitors in AML$319,550
R01 · FY2016 · CA · contact PI
Targeting the aberrant kinome-epigenome in AML$308,958
R01 · FY2016 · CA · contact PI
Training Hematology and Oncology Fellows in Clinical Research$203,478
T32 · FY2016 · CA · contact PI
Developing CRM1 inhibitors in AML$319,550
R01 · FY2015 · CA · contact PI
Targeting the aberrant kinome-epigenome in AML$307,671
R01 · FY2015 · CA · contact PI
Developing CRM1 inhibitors in AML$319,550
R01 · FY2014 · CA · contact PI
Targeting the aberrant kinome-epigenome in AML$300,231
R01 · FY2014 · CA · contact PI
MicroRNAs as biomarkers for acute graft-versus-host disease$113,190
R21 · FY2014 · HL · contact PI
Targeting the aberrant kinome-epigenome in AML$291,226
R01 · FY2013 · CA · contact PI
MicroRNAs as biomarkers for acute graft-versus-host disease$115,156
R21 · FY2013 · HL · contact PI
Targeting the aberrant kinome-epigenome in AML$310,414
R01 · FY2012 · CA · contact PI
Role of the ultraconserved genomic regions (UCRs) in hematopoiesis$190,625
R21 · FY2011 · HL · contact PI
Role of the ultraconserved genomic regions (UCRs) in hematopoiesis$228,750
R21 · FY2010 · HL · contact PI